FDA Grants Breakthrough Therapy Designation For Genentech ’s Hemlibra (emicizumab-kxwh) in Hemophilia A Without Inhibitors

South San Francisco, CA -- April 16, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news